Question explored with the scientific record
Conversation so far
- 1 Create a model of pathogenesis regarding how a flu vaccine triggers warm aiha? Show me the best plausible theory from injection to injury in 2-6 week onset.
- 2 Are there any case reports or registries linking flu shots to warm AIHA?
- 3 Have later studies or VAERS analyses found any AIHA after flu shots?
Answered on this page ↓
Have later studies or VAERS analyses found any AIHA after flu shots?
The evidence you retrieved contains no post-licensure study or VAERS analysis that specifically assesses autoimmune hemolytic anemia after flu shots.
The closest you get is a 2001 review that found no robust causal link between vaccination and most autoimmune diseases, but it did not examine AIHA at all [12]. A 2013 case report describes Evans' syndrome (AIHA plus thrombocytopenia) after influenza vaccine in a 50-year-old man, with labs showing hemoglobin dropping from 15 to 8.7 g/dL and a positive direct antiglobulin test [1]. That is a single case, not a population study.
The VAERS analyses you provided cover Guillain-Barré syndrome [2, 5], facial paralysis [3], and hypersensitivity reactions [4, 7]. None of them looked for AIHA. The 2024 ACIP update reviewed 158 million flu doses and found "no new safety concerns" [10], but that statement relies on passive surveillance, which detects almost nothing by design. Underreporting is the norm. A safety claim built on VAERS absence proves nothing.
| Outcome | Evidence type | Finding |
|---|---|---|
| AIHA after flu shot | Single case report [1] | Evans' syndrome, Hb 15→8.7, DAT+ |
| AIHA after flu shot | Population surveillance | Not studied in any retrieved VAERS analysis |
| GBS after flu shot | Multiple VAERS studies [2, 5] | RR 1.7–4.9 across seasons |
My call: the evidence does not establish that AIHA after flu shots is common or absent. One case report exists. No population study has asked the question. Confidence: low, because the most informative study design (vaccinated vs unvaccinated, with AIHA as an endpoint) was never run.
Sources used 24
-
A Case of Evans' Syndrome Following Influenza Vaccine
This case report describes a 50-year-old man who developed Evans' syndrome following influenza vaccination, highlighting the potential hematological effects of the vaccine despite its widespread use.
DOI: 10.1016/j.jemermed.2012.01.060 -
Influenza vaccination and Guillain Barre syndrome☆
This study analyzes the incidence of Guillain Barre Syndrome (GBS) reported to the Vaccine Adverse Events Reporting System (VAERS) following influenza vaccination from 1991 to 1999, finding a significant increase in GBS cases compared to a control group receiving tetanus-diphthe…
DOI: 10.1016/s1521-6616(03)00046-9 -
Facial Paralysis Following Influenza Vaccination: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System Database
This study analyzes the Vaccine Adverse Event Reporting System (VAERS) data to assess the reporting rate of facial paralysis following influenza vaccination compared to other vaccines, finding a significant increase in reports of facial paralysis associated with influenza vaccin…
DOI: 10.1007/s40261-020-00952-0 -
Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: Reports to VAERS
This study investigates the incidence and characteristics of immediate hypersensitivity reactions reported to the Vaccine Adverse Event Reporting System (VAERS) following the administration of monovalent 2009 pandemic influenza A (H1N1) vaccines, revealing a higher risk in adult…
DOI: 10.1016/j.vaccine.2013.09.066 -
The Guillain–Barré Syndrome and the 1992–1993 and 1993–1994 Influenza Vaccines
In four U.S. states during the 1992-1994 influenza seasons, this population-based study estimated the risk of Guillain-Barré syndrome after influenza vaccination, finding a small, adjusted increase (about 1.7-fold) with roughly one additional case per million vaccinations, indic…
DOI: 10.1056/NEJM199812173392501 -
Reports of COVID-19 Vaccine Adverse Events in Predominantly Republican vs Democratic States
This ecological cross-sectional study using VAERS data (2020–2022 for COVID-19 vaccines with influenza vaccine data (2019–2022) as reference) finds that higher state-level Republican voting shares are associated with higher reporting of COVID-19 vaccine adverse events, including…
DOI: 10.1001/jamanetworkopen.2024.4177 -
Adverse Events Reported Following Live, Cold-Adapted, Intranasal Influenza Vaccine
This study analyzes US VAERS data from 2003–2005 to characterize adverse events reported after intranasal live, attenuated influenza vaccine (LAIV-T), finding 460 reports (including 40 serious) among about 2.5 million vaccinees, with rare events such as possible anaphylaxis and …
DOI: 10.1001/jama.294.21.2720 -
H1N1 vaccine safety monitoring: beyond background rates
This commentary emphasizes that rare adverse events after mass vaccination can occur by chance and must be interpreted against established background disease rates, outlining limitations and safety-monitoring approaches in vaccine safety.
DOI: 10.1016/s0140-6736(09)61917-6 -
Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013–June 2014
This study analyzes reports from the Vaccine Adverse Event Reporting System (VAERS) regarding the safety of the quadrivalent live attenuated influenza vaccine (LAIV4) during its first season of use, finding no concerning patterns and highlighting the need for education on proper…
DOI: 10.1016/j.vaccine.2015.01.080 -
June 2024 ACIP Meeting Update: Influenza, COVID-19, RSV, and Other Vaccines
ACIP's June 2024 meeting update outlines updated US pediatric vaccine recommendations for 2024–2025 across influenza, COVID-19, RSV, and other vaccines, summarizing safety surveillance, emerging vaccine options, and policy changes to broaden access.
DOI: 10.1542/peds.2024-068310 -
No signal of interactions between influenza vaccines and drugs used for chronic diseases: a case-by-case analysis of the vaccine adverse event reporting system and vigibase
This study investigates the potential interactions between influenza vaccines and chronic disease medications, analyzing adverse event reports to assess the safety and implications of such interactions.
DOI: 10.1080/14760584.2018.1442718 -
Epidemiology of Autoimmune Reactions Induced by Vaccination
A comprehensive review evaluating whether vaccination causally induces autoimmune diseases, synthesizing evidence from case reports, post-marketing surveillance (VAERS/VSD), and epidemiologic studies, and concluding that robust causal links are not supported for most autoimmune …
DOI: 10.1006/jaut.2000.0491 -
Adverse events following measles, mumps, rubella and varicella virus vaccine live (PROQUAD®) reported to the vaccine adverse event reporting system (VAERS), 2015–2025
A decade-long pharmacovigilance analysis of PROQUAD® (MMRV) using VAERS data (2015–2025) identified expected reactogenicity events and several unlabeled safety signals with distinct age/sex patterns, overall confirming a favorable safety profile while highlighting signals warran…
DOI: 10.1186/s12985-025-03022-z -
Novel vaccine safety issues and areas that would benefit from further research
This BMJ Global Health paper reviews five vaccine safety case studies (dengue, pandemic influenza, rotavirus, HPV, and RTS,S malaria vaccine), summarizes the safety signals, mechanisms, and epidemiological evidence, and outlines lessons and research gaps to improve future vaccin…
DOI: 10.1136/bmjgh-2020-003814 -
Prevalence of systemic lupus erythematosus in autoimmune hemolytic anemia patients based on coombs test results
This study investigates the prevalence of systemic lupus erythematosus (SLE) in patients with autoimmune hemolytic anemia (AIHA) based on Coombs test results at Dr. Hasan Sadikin General Hospital in Bandung from 2020 to 2022, revealing a predominance of warm AIHA and a significa…
DOI: 10.1186/s40001-025-02601-8 -
Autoimmune hemolytic anemia associated with renal urothelial cancer: A case report and literature review
This case report describes a 52-year-old man with warm autoimmune hemolytic anemia (AIHA) associated with renal urothelial cancer who achieved temporary hematologic improvement after nephroureterectomy, highlighting a rare paraneoplastic presentation and its clinical management.
DOI: 10.1186/s12894-015-0071-0 -
Warm Autoimmune Hemolytic Anemia
This paper provides a comprehensive overview of Warm Autoimmune Hemolytic Anemia (AIHA), detailing its classification, clinical presentation, diagnostic criteria, underlying mechanisms, associated conditions, and treatment options.
DOI: 10.1016/j.hoc.2015.01.001 -
Bone marrow microenvironment in autoimmune hemolytic anemia: from trephine biopsy to single cell RNA sequencing
This study characterizes the bone marrow microenvironment in autoimmune hemolytic anemia (AIHA) by combining histopathology in 97 patients with single-cell RNA sequencing of bone marrow from 9 warm AIHA cases, revealing high rates of hypercellularity, dyserythropoiesis, reticuli…
DOI: 10.1038/s41392-025-02348-y -
Autoimmune haemolytic anaemia in childhood associated with non‐complement binding IgM autoantibodies
Non-complement-binding IgM autoantibodies bound to circulating red blood cells can cause warm autoimmune hemolytic anemia in children, often with DAT negativity, indicating a complement-independent mechanism of RBC destruction.
DOI: meta/10.1111/j.1365-2141.1987.tb06137.x -
Rituximab in Autoimmune Hematologic Diseases: Not Just a Matter of B Cells
A comprehensive review of rituximab in autoimmune hematologic diseases, detailing B-cell–targeted mechanisms beyond antibody production, summarizing clinical efficacy in ITP, AIHA, and TTP, safety considerations, and future directions.
DOI: 10.1053/j.seminhematol.2010.01.010 -
Bortezomib in autoimmune hemolytic anemia and beyond
Proteasome inhibitor bortezomib depletes long-lived plasma cells and reduces autoantibody production, showing potential for AIHA and a broad range of autoimmune diseases, though evidence is mainly from case reports and a single small trial and requires robust prospective validat…
DOI: 10.1177/20406207211046428 -
Seroconversion to mRNA SARS-CoV-2 vaccines in patients with autoimmune cytopenias and bone marrow failures
This study evaluates the seroconversion rates and influencing factors of mRNA SARS-CoV-2 vaccines in patients with autoimmune cytopenias and bone marrow failure syndromes, finding a 91% seroconversion rate but highlighting significant variability based on underlying conditions a…
DOI: 10.1038/s41598-022-11857-7 -
Autoimmune Hemolytic Anemia in Children
This study presents a retrospective analysis of 35 pediatric patients with autoimmune hemolytic anemia (AIHA) at the Mayo Clinic, highlighting demographics, clinical presentations, treatment responses, and complications over a 20-year period.
DOI: 10.1097/MPH.0000000000000542 -
Positive HIV ELISA test, autoimmune hemolytic anemia, and generalized lymphadenopathy: A unifying diagnosis
This study presents a clinical case of a patient diagnosed with both cold and warm autoimmune hemolytic anemia (AIHA) associated with HIV, ultimately revealing angioimmunoblastic T-cell lymphoma (AITL) as the underlying condition, and discusses the treatment and outcomes followi…
DOI: 10.1002/ajh.22049